Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Bibliographic Details
Main Authors:	Preiss, D, Herrington, W, Haynes, R
Format:	Conference item
Language:	English
Published:	American Heart Association 2022

Similar Items

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
by: Nangaku, M, et al.
Published: (2024)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
by: Staplin, N, et al.
Published: (2023)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

Empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2022)

Long-term effects of empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2024)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
by: Herrington, W, et al.
Published: (2022)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
by: Judge, PK, et al.
Published: (2023)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
by: Coleman, R, et al.
Published: (2017)

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
by: Hundertmark, MJ, et al.
Published: (2021)

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
by: Coleman, RL, et al.
Published: (2020)

SERUM LIPIDS DO NOT PREDICT CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS
by: Landray, M, et al.
Published: (2005)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
by: Zhu, D, et al.
Published: (2025)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Lipids in chronic kidney disease.
by: Lewis, D, et al.
Published: (2010)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
by: Zhu, D, et al.
Published: (2025)

Chronic kidney disease, heart failure and neprilysin inhibition
by: Haynes, R, et al.
Published: (2019)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Metformin: the safest hypoglycaemic agent in chronic kidney disease?
by: Nye, H, et al.
Published: (2011)

Neprilysin inhibition in chronic kidney disease.
by: Judge, P, et al.
Published: (2014)

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial
by: Hundertmark, MJ, et al.
Published: (2023)

Chronic kidney disease
by: de Lusignan, S
Published: (2006)

The role of lipoprotein(a) in chronic kidney disease
by: Hopewell, J, et al.
Published: (2018)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
by: Judge, PK, et al.
Published: (2024)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial
by: Hobbs, FDR, et al.
Published: (2024)

Commentary: Controversies in NICE guidance on chronic kidney disease.
by: Landray, M, et al.
Published: (2008)

Commentary: Controversies in NICE guidance on chronic kidney disease
by: Landray, M, et al.
Published: (2008)

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease
by: Judge, PK, et al.
Published: (2021)

Which cardiovascular risk factors matter in chronic kidney disease?
by: Baigent, C, et al.
Published: (2007)

Genetic loci influencing kidney function and chronic kidney disease.
by: Chambers, J, et al.
Published: (2010)

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?
by: Haynes, R, et al.
Published: (2013)

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?
by: Haynes, R, et al.
Published: (2013)

Metformin use in chronic kidney disease: new evidence to guide dosing.
by: Herrington, W, et al.
Published: (2013)

Is “chronic kidney disease” a disease?
by: Smart, B, et al.
Published: (2018)

Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data
by: Dmitrieva, O, et al.
Published: (2013)